The Effects of COVID-19 on Patient Experience and Price Transparency


Ogi Kwon, of R1 Revenue Cycle Management (RCM) offers insights on lessons learned from the COVID-19 pandemic and the future of price transparency.

The COVID-19 pandemic provides an opportunity for organizations to think about how they can be proactive and monitor new regulatory changes in real time, said Ogi Kwon, a manager in the regulatory team at R1 RCM's advisory and assurance department.

In this interview with Chief Healthcare Executive™, Kwon explains how he feels price transparency as a whole while be something that continues to be iterated upon going forward and how requirements could take different forms.

R1 RCM is a revenue cycle management company that offers technology-driven solutions to transform health care providers' patient experience and financial performance.

Related Videos
Jim Adams, AllianceRx Walgreens Prime
Heather Bonome, Pharm.D., URAC
George Van Antwerp, MBA
Jesse Fasolo
Related Content
© 2023 MJH Life Sciences

All rights reserved.